No abstract available
Keywords:
Atezolizumab; Immune checkpoint inhibitor rechallenge; Immunotherapy; Lung cancer; Nivolumab.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents, Immunological / pharmacology
-
B7-H1 Antigen / antagonists & inhibitors*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Humans
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Nivolumab / pharmacology*
-
Prognosis
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
Immune Checkpoint Inhibitors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
atezolizumab